SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
46.21
-0.09 (-0.19%)
May 1, 2025, 4:00 PM EDT - Market closed

Company Description

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.

It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial.

In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations.

The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain.

SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics logo
Country United States
Founded 2017
IPO Date Sep 13, 2019
Industry Biotechnology
Sector Healthcare
Employees 368
CEO Saqib Islam

Contact Details

Address:
100 Washington Boulevard
Stamford, Connecticut 06902
United States
Phone 203 883 9490
Website springworkstx.com

Stock Details

Ticker Symbol SWTX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0000813619
CUSIP Number 85205L107
ISIN Number US85205L1070
Employer ID 94-2551470
SIC Code 3081